Using the IMEDS distributed database for epidemiological studies in type 2 diabetes mellitus
Open Access
- 19 December 2022
- journal article
- research article
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 10 (6) , e002916
Abstract
Introduction: This study aimed to assess data relevancy and data quality of the Innovation in Medical Evidence Development and Surveillance System Distributed Database (IMEDS-DD) for diabetes research and to evaluate comparability of its type 2 diabetes cohort to the general type 2 diabetes population. Research design and methods: A retrospective study was conducted using the IMEDS-DD. Eligible members were adults with a medical encounter between April 1, 2018 and March 31, 2019 (index period). Type 2 diabetes and co-existing conditions were determined using all data available from April 1, 2016 to the most recent encounter within the index period. Type 2 diabetes patient characteristics, comorbidities and hemoglobin A1c (HbA1c) values were summarized and compared with those reported in national benchmarks and literature. Results: Type 2 diabetes prevalence was 12.6% in the IMEDS-DD. Of 4 14 672 patients with type 2 diabetes, 52.8% were male, and the mean age was 65.0 (SD 13.3) years. Common comorbidities included hypertension (84.5%), hyperlipidemia (82.8%), obesity (45.3%), and cardiovascular disease (44.7%). Moderate-to-severe chronic kidney disease was observed in 20.2% patients. The most commonly used antihyperglycemic agents included metformin (35.7%), sulfonylureas (14.8%), and insulin (9.9%). Less than one-half (48.9%) had an HbA1c value recorded. These findings demonstrated the notable similarity in patient characteristics between type 2 diabetes populations identified within the IMEDS-DD and other large databases. Conclusions: Despite the limitations related to HbA1c data, our findings indicate that the IMEDS-DD contains robust information on key data elements to conduct pharmacoepidemiological studies in diabetes, including member demographic and clinical characteristics and health services utilization.Keywords
Funding Information
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ USA, in collaboration with Pfizer Inc., New York, NY, USA (N/A)
This publication has 17 references indexed in Scilit:
- A scheme based on ICD-10 diagnoses and drug prescriptions to stage chronic kidney disease severity in healthcare administrative recordsClinical Kidney Journal, 2017
- Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitusCurrent Medical Research and Opinion, 2016
- Changes in Characteristics and Treatment Patterns of Patients with Newly Diagnosed Type 2 Diabetes in a Large United States Integrated Health System between 2008 and 2013Clinical Medicine Insights: Endocrinology and Diabetes, 2016
- Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) stagingBMC Research Notes, 2014
- The U.S. Food and Drug Administration's Mini‐Sentinel program: status and directionPharmacoepidemiology and Drug Safety, 2012
- A policy framework for public health uses of electronic health dataPharmacoepidemiology and Drug Safety, 2012
- A combined comorbidity score predicted mortality in elderly patients better than existing scoresJournal of Clinical Epidemiology, 2011
- Developing the Sentinel System — A National Resource for Evidence DevelopmentNew England Journal of Medicine, 2011
- Prevalence of Lower-Extremity Disease in the U.S. Adult Population ≥40 Years of Age With and Without DiabetesDiabetes Care, 2004
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987